论文部分内容阅读
目的 探讨 2SHRZ及 2S3 H3 R3 Z3 两组化疗方案在抗肺结核强化期治疗中对肝功能的影响情况。方法 抽取 2 0 0 0年至 2 0 0 2年在本院就诊的乙型病毒性肝炎表面抗原 (HBsAg)阴性的肺结核患者 191例 ,其中2SHRZ组及 2S3 H3 R3 Z3 组分别为 87例和 10 4例 ,观察其两个月治疗期间患者肝功能的情况并进行对比分析。结果 2SHRZ组及 2S3 H3 R3 Z3 组治疗后出现肝功能异常者分别为 9例和 13例 ,轻度血清谷丙转氨酶 (ALT)升高患者 (4 0～ 10 0U/L)分别为 6例和 11例 ;而中重度ALT升高者 (≥ 10 0U/L)分别为 3例和 2例 ;两组间各项指标对比差异均无显著性 (P >0 .0 5 )。结论 在无其它不良因素影响下 ,2S3 H3 R3 Z3 治疗后引起的肝功能损害的机会及程度与 2SHRZ相当 ,肝损发生率皆不高 ,以轻度肝细胞损伤为主 ;2S3 H3 R3 Z3 方案既安全、疗效肯定、服用方便、经济 ,值得在抗肺结核强化期治疗中推广使用
Objective To investigate the effects of two chemotherapy regimens of 2SHRZ and 2S3 H3 R3 Z3 on liver function in the treatment of intensive pulmonary tuberculosis. Methods A total of 191 pulmonary tuberculosis patients with negative HBsAg in our hospital from 2000 to 2002 were selected, including 87 cases in the 2SHRZ group and 87 cases in the 2S3 H3 R3 Z3 group 4 cases were observed during the two-month treatment of patients with liver function and comparative analysis. Results In the 2SHRZ group and the 2S3H3R3Z3 group, there were 9 and 13 cases of abnormal liver function after treatment. The patients with elevated serum ALT level (40 ~ 100U / L) were 6 and 11 cases, while those with moderate to severe ALT (≥10 0U / L) were 3 and 2 cases respectively. There was no significant difference between the two groups (P> 0.05). Conclusions There was no other adverse factors in the treatment of 2S3 H3 R3 Z3 liver function damage caused by the chance and degree of 2SHRZ considerable, the incidence of liver damage are not high, with mild hepatotoxicity; 2S3 H3 R3 Z3 program Both safe, effective, easy to take, economical, it is worth to promote the use of intensive treatment of anti-pulmonary tuberculosis